Holen Sie sich die Stockscreener-App
0.8964
3.26%
0.0283
Handel nachbörslich:
.87
-0.0264
-2.95%
Schlusskurs vom Vortag:
$0.8681
Offen:
$0.82
24-Stunden-Volumen:
3.28M
Relative Volume:
0.63
Marktkapitalisierung:
$8.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.21M
KGV:
-16.36
EPS:
-0.0548
Netto-Cashflow:
-
1W Leistung:
+51.93%
1M Leistung:
-17.76%
6M Leistung:
-91.27%
1J Leistung:
-99.72%
1-Tages-Spanne:
$0.70
$0.94
1-Wochen-Bereich:
$0.51
$1.40
52-Wochen-Spanne:
$0.51
$350.00
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Firmenname
Conduit Pharmaceuticals Inc
Sektor
Branche
Telefon
(646) 491 9132
Adresse
4851 TAMIAMI TRAIL NORTH, NAPLES
Vergleichen Sie CDT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDT
Conduit Pharmaceuticals Inc
|
0.8964 | 8.56M | 0 | -4.21M | 0 | -0.0548 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.49 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.91 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.38 | 36.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.93 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.84 | 25.73B | 3.81B | -644.79M | -669.77M | -6.24 |
Conduit Pharmaceuticals Inc Aktie (CDT) Neueste Nachrichten
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program - The Manila Times
Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan
Conduit Pharmaceuticals expands partnership with Sarborg - MSN
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization - The Manila Times
Machine Learning Deal: How Conduit Pharma Plans to Revolutionize Drug Development - Stock Titan
Analyzing Conduit Pharmaceuticals (CDT) and Its Competitors - Defense World
Conduit Pharmaceuticals meets Nasdaq listing standards By Investing.com - Investing.com Australia
Conduit Pharmaceuticals meets Nasdaq listing standards - Investing.com
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - The Manila Times
Major Patent Win: Conduit's Autoimmune Drug Gets 20-Year Market Protection - Stock Titan
Conduit Pharmaceuticals Inc. (CDT) reports earnings - Quartz
CONDUIT PHARMACEUTICALS INC. SEC 10-K Report - TradingView
CONDUIT PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Conduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656 - Nasdaq
Conduit Pharmaceuticals progresses in autoimmune drug studies By Investing.com - Investing.com Australia
Conduit Pharmaceuticals progresses in autoimmune drug studies - Investing.com
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904 - The Manila Times
Conduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline Development - Nasdaq
Conduit's Triple-Drug Pipeline Shows Promise for Lupus TreatmentMajor R&D Breakthrough - StockTitan
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update - The AM Reporter
Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer - MarketScreener
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel - The Manila Times
Conduit Pharmaceuticals secures Nasdaq extension - Investing.com
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining - Nasdaq
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - StockTitan
Conduit Pharmaceuticals secures Nasdaq extension By Investing.com - Investing.com Australia
Conduit Pharmaceuticals Inc (NASDAQ: CDT) Is Down -83.09% So Far This Year: What Will Happen Next? - Stocks Register
Taking a look at what insiders are doing to gauge the Conduit Pharmaceuticals Inc (CDT)’s direction - Knox Daily
Conduit Pharmaceuticals Advances Phase II AI Collaboration With Sarborg To Enhance Drug Development - Nasdaq
Conduit Progresses Phase II of its AI Initiative with Sarborg - The Manila Times
How Conduit's New AI System Could Revolutionize Drug Development Decision-Making - StockTitan
Conduit Pharmaceuticals acts to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Conduit Pharmaceuticals acts to regain Nasdaq compliance - Investing.com India
Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common StockSEC Filing - Marketscreener.com
Conduit Pharmaceuticals Awaits Nasdaq Decision on Compliance - TipRanks
Understanding the Risks of Investing in Conduit Pharmaceuticals Inc (CDT) - Knox Daily
Conduit Pharmaceuticals to execute 1-for-100 reverse stock split - MSN
Conduit Pharmaceuticals enacts reverse stock split to meet Nasdaq standards - MSN
Conduit Pharmaceuticals, Charles River Laboratories Partner to Evaluate Potential Lupus Treatment - Marketscreener.com
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model - The Manila Times
Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - StockTitan
Weekly TechBio News 🤹 - substack.com
Conduit Pharmaceuticals announces debt repayment and partial conversion of senior secured note - MSN
Small Cap Stocks To Watch NowFebruary 09th - MarketBeat
Promising Small Cap Stocks To Keep An Eye OnFebruary 07th - MarketBeat
Conduit Pharmaceuticals settles debt, converts senior note - MSN
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note - The Manila Times
Conduit Pharmaceuticals settles debt, converts senior note By Investing.com - Investing.com Australia
Finanzdaten der Conduit Pharmaceuticals Inc-Aktie (CDT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):